Biomimetic & Biohybrid Materials, Biomedical Devices, and Drug Delivery Laboratories, Department of Biomedical Engineering, Rowan University, Glassboro, NJ 08028, USA.
OcuMedic, Inc. Mullica Hill, NJ, USA.
Transl Vis Sci Technol. 2021 Dec 1;10(14):5. doi: 10.1167/tvst.10.14.5.
This work demonstrates seven-day controlled and extended in vitro physiological flow dual release of multiple post-ocular surgery therapeutics from extended-wear contact lenses as a dropless alternative for treatment of uveitis and corneal inflammation, pain, and infection. Lens replacement each week optimizes treatment matching patient recall time with the ability to increase or decrease dosage.
Lenses were synthesized using molecular imprinting to create lenses with macromolecular memory for diclofenac sodium (DS) and dexamethasone sodium phosphate (DMSP), as well as bromfenac sodium (BS) and moxifloxacin (MOX). Drug uptake and release were analyzed, and physical properties were measured and compared to commercial standards.
DS + DMSP-loaded lenses demonstrated seven-days-plus release of each, whereas controls released more than 85% of their payload within the first day. Lenses loaded with BS + MOX demonstrated release of BS and MOX for 11 and eight days, respectively. Structural analysis demonstrated statistically similar mesh size and average molecular weight between crosslinks between imprinted lenses and controls, suggesting that release extension was due to formation of macromolecular memory sites rather than a tighter polymer architecture.
Lenses demonstrated in this work have significant clinical applications as an eye drop alternative, possessing the ability to be worn continuously for one week while delivering a consistent amount of therapeutic for the duration of wear.
In vitro physiological flow release results demonstrate the clinical potential of therapeutic contact lenses as a dropless vehicle for ocular drug delivery.
本研究旨在展示一种新型隐形眼镜，它能够在体外持续七天控制并延长释放多种眼后手术治疗药物，为治疗葡萄膜炎和角膜炎症、疼痛及感染提供一种无滴剂替代疗法。每周更换镜片可以优化治疗效果，使患者的治疗时间与药物剂量的增减相匹配。
采用分子印迹技术合成隐形眼镜，使镜片具有对双氯芬酸钠（DS）和地塞米松磷酸二钠（DMSP）以及溴芬酸钠（BS）和莫西沙星（MOX）的大分子记忆功能。分析药物摄取和释放情况，并测量和比较物理性能与商业标准。
载有 DS+DMSP 的隐形眼镜实现了每种药物长达七天以上的持续释放，而对照隐形眼镜在第一天内释放了超过 85%的药物。载有 BS+MOX 的隐形眼镜分别释放 BS 和 MOX 长达 11 天和 8 天。结构分析表明，印迹隐形眼镜和对照隐形眼镜之间的交联平均分子量和平均分子量之间具有统计学上相似的网格尺寸，这表明释放时间的延长是由于形成了大分子记忆位点，而不是聚合物结构更紧密。
本研究中的隐形眼镜具有显著的临床应用潜力，可作为一种替代滴眼液的隐形眼镜，能够连续佩戴一周，同时在佩戴期间持续输送恒定剂量的治疗药物。
体外生理流动释放结果表明，治疗性隐形眼镜作为一种无滴剂眼内药物输送载体具有潜在的临床应用前景。
